IOVA
$3.88-0.16 (-4.08%)
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the Unite...
Recent News
Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 24, Iovance Biotherapeutics announced positive early data from a pilot clinical trial evaluating its lifileucel TIL cell therapy in patients with advanced soft tissue sarcomas. The study focused on individuals with metastatic or unresectable undifferentiated pleomorphic […]
Iovance Sarcoma Trial Data Puts TIL Platform And Stock In Focus
Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on these data. This program extends Iovance's tumor infiltrating lymphocyte (TIL) cell therapy platform beyond its approved melanoma use. Iovance Biotherapeutics (NasdaqGM: IOVA) is putting fresh attention on its TIL platform, with lifileucel now moving from a pilot study in advanced sarcoma...
Iovance (IOVA) Soars 33%, Hits All-Time High
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Stocks Investors Are Watching Closely This Week. Iovance soared by 32.9 percent week-on-week to hit a new all-time high after an analyst doubled its price target for the stock, while investors loaded portfolios ahead of business updates next week. In its market report, investment firm UBS […]
Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine
Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and support the pharma-maker’s oncology portfolio and other therapeutic offerings. As part of the agreement, Merck will leverage Tempus […]
Iovance (IOVA) Hits 52-Week High as Analyst Doubles Price Target
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the 10 Stocks to Watch Right Now. Iovance climbed to a new 52-week high on Friday, extending a three-day run, as investors gobbled up shares after an investment firm doubled its price target for its stock. At intra-day trading, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) climbed to its highest price […]